Advances in Managing NTRK Fusion-Positive CNS Cancers Treatment With TRK Inhibitors for Primary CNS Tumors
hosted byProjects In Knowledge Inc. (PIK)Advances in Managing NTRK Fusion-Positive CNS Cancers Treatment With TRK Inhibitors for Primary CNS Tumors is organized by Projects In Knowledge Inc. (PIK).
Release Date: Jun 01, 2023
Termination Date: May 31, 2024
Activity Goal:
The goal of this activity is to provide the most current clinical information and practical management strategies in treating CNS tumors, as seen in clinical practice, in a customized, interactive, and easily digestible on-demand educational program.
Learning Objective(s):
• Analyze the most recent clinical trial data regarding newly FDA-approved tropomyosin receptor kinase (TRK) inhibitors for the treatment of primary central nervous system (CNS) cancers.
• Integrate TRK inhibitors into evolving CNS tumor treatment paradigms.
Additional details will be posted as soon as information is available.
